A vaccine won’t solve all our Covid problems
Today’s Oxford-AstraZeneca vaccine update has raised hopes that life in Britain could start getting back to normal by spring. But cheers in Downing Street didn’t extend to AstraZeneca’s share price, which fell by nearly three per cent in response to the news. Why the dip in the wake of such good news? AstraZeneca vaccine’s effectiveness – recorded
![](https://www.spectator.co.uk/wp-content/uploads/2020/11/GettyImages-1229736237.jpg?resize=440,293)